常三帅,刘新民,姜正明,马为,董建增,宋光远

• 1:首都医科大学附属北京安贞医院心脏瓣膜病介入中心国家心血管病临床医学研究中心
• 2:北京大学第一医院心内科
• 3:首都医科大学附属北京安贞医院心力衰竭中心国家心血管病临床医学研究中心

摘要(Abstract)：

虽然心力衰竭（心衰）的药物和器械治疗均取得了较大进步，但心衰患者整体仍预后较差。心衰的血流动力学异常表现为左心房压升高和肺淤血，既往研究表明降低左心房压可改善心衰患者的症状和预后，因此左心系统超负荷可能是心衰治疗的一个潜在靶点。心房分流术旨在制造一定程度稳定可控的左向右心内分流，将心衰患者失代偿的左心容量和压力负荷恢复至代偿状态，从而改善心衰症状及预后，目前全球范围内仍处于临床研究阶段，已有数据表明心房分流术可降低心衰患者静息或运动时左心房压，改善肺淤血，提高患者活动耐量和临床心功能，但尚无研究证实其可以改善心衰再入院和死亡等临床终点事件。未来的研究重点在于筛选能从心房分流术中获益的心衰患者，明确心衰病因、右心功能和肺血管阻力可逆性的评估以及依据射血分数的心衰分型可能是筛选患者的关键因素。

关键词(KeyWords)： 心力衰竭;心房分流;左心房压;肺毛细血管楔压;肺动脉压

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 常三帅,刘新民,姜正明,马为,董建增,宋光远

参考文献(References)：

• [1] Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics-2023 update:a report from the American Heart Association[J]. Circulation, 2023, 147(8):e93-e621.DOI:10.1161/CIR.0000000000001123.
• [2]中国心血管健康与疾病报告编写组.《中国心血管健康与疾病报告2022》概要[J].中国介入心脏病学杂志，2023, 31(7):485-508. DOI:10.3969/j.issn.1004-8812.2023.07.002.
• [3]中国心衰中心联盟，苏州工业园区心血管健康研究院，中国心血管健康联盟，中国心衰中心工作报告（2021）——心力衰竭患者的诊疗现况[J].中国介入心脏病学杂志，2022,30(5):328-336. DOI:10.3969/j.issn.1004-8812.2022.05.002.
• [4] Dorfs S, Zeh W, Hochholzer W, et al. Pulmonary capillary wedge pressure during exercise and long-term mortality in patients with suspected heart failure with preserved ejection fraction[J].Eur Heart J, 2014,35(44):3103-3112. DOI:10.1093/eurheartj/ehu315.
• [5] Rosenkranz S, Gibbs JS, Wachter R, et al. Left ventricular heart failure and pulmonary hypertension[J]. Eur Heart J,2016, 37(12):942-954. DOI:10.1093/eurheartj/ehv512.
• [6] Schiff GD, Fung S, Speroff T, et al. Decompensated heart failure:symptoms, patterns of onset, and contributing factors[J]. Am J Med, 2003, 114(8):625-630. DOI:10.1016/s0002-9343(03)00132-3.
• [7] Gustafsson F. Interatrial shunt devices for heart failure[J]. Nat Rev Cardiol, 2023, 20(11):717-718. DOI:10.1038/s41569-023-00923-w.
• [8] Guazzi M, Ghio S, Adir Y. Pulmonary hypertension in HFpEF and HFrEF:JACC review topic of the week[J]. J Am Coll Cardiol, 2020,76(9):1102-1111. DOI:10.1016/j.jacc.2020.06.069.
• [9]中华医学会心血管病学分会肺血管病学组，中华心血管病杂志编辑委员会.中国肺高血压诊断和治疗指南2018[J].中华心血管病杂志，2018,46(12):933-964. DOI:10.3760/cma.j.issn.0253-3758.2018.12.006.
• [10] Crawford MH. Iatrogenic Lutembacher’s syndrome revisited[J]. Circulation, 1990, 81(4):1422-1424. DOI:10.1161/01.cir.81.4.1422.
• [11] Masutani S, Senzaki H. Left ventricular function in adult patients with atrial septal defect:implication for development of heart failure after transcatheter closure[J]. J Card Fail, 2011, 17(11):957-963. DOI:10.1016/j.cardfail.2011.07.003.
• [12] Mlcek M, Meani P, Cotza M, et al. Atrial septostomy for left ventricular unloading during extracorporeal membrane oxygenation for cardiogenic shock:animal model[J]. JACC Cardiovasc Interv, 2021,14(24):2698-2707. DOI:10.1016/j.jcin.2021.09.011.
• [13] Abraham WT, Adamson PB, Bourge RC, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure:a randomised controlled trial[J]. Lancet, 2011,377(9766):658-666. DOI:10.1016/S0140-6736(11)60101-3.
• [14] Ritzema J, Troughton R, Melton I, et al. Physician-directed patient self-management of left atrial pressure in advanced chronic heart failure[J]. Circulation, 2010, 121(9):1086-1095.DOI:10.1161/CIRCULATIONAHA.108.800490.
• [15] Hasenfu?G, Hayward C, Burkhoff D, et al. A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction(REDUCE LAP-HF):a multicentre, openlabel, single-arm, phase 1 trial[J]. Lancet, 2016,387(10025):1298-1304. DOI:10.1016/S0140-6736(16)00704-2.
• [16] Del Trigo M, Bergeron S, Bernier M, et al. Unidirectional left-to-right interatrial shunting for treatment of patients with heart failure with reduced ejection fraction:a safety and proof-ofprinciple cohort study[J]. Lancet, 2016,387(10025):1290-1297. DOI:10.1016/S0140-6736(16)00585-7.
• [17] Kaye DM, Petrie MC, McKenzie S, et al. Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction[J]. ESC Heart Fail, 2019,6(1):62-69. DOI:10.1002/ehf2.12350.
• [18] Feldman T, Mauri L, Kahwash R, et al. Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction(REDUCE LAP-HFⅠ[Reduce Elevated Left Atrial Pressure in Patients With Heart Failure])[J]. Circulation, 2018, 137(4):364-375. DOI:10.1161/CIRCULATIONAHA.117.032094.
• [19] Shah SJ, Feldman T, Ricciardi MJ, et al. One-year safety and clinical outcomes of a transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction in the reduce elevated left atrial pressure in patients with heart failure(REDUCE LAP-HFⅠ)trial:a randomized clinical trial[J]. JAMA Cardiol, 2018,3(10):968-977. DOI:10.1001/jamacardio.2018.2936.
• [20] Shah SJ, Borlaug BA, Chung ES, et al. Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction(REDUCE LAP-HFⅡ)：a randomised, multicentre,blinded, sham-controlled trial[J]. Lancet, 2022,399(10330):1130-1140. DOI:10.1016/S0140-6736(22)00016-2.
• [21] Borlaug BA, Blair J, Bergmann MW, et al. Latent pulmonary vascular disease may alter the response to therapeutic atrial shunt device in heart failure[J]. Circulation, 2022,145(21):1592-1604. DOI:10.1161/CIRCULATIONAHA.122.059486.
• [22] Pfeiffer M, Boehmer J, Gorcsan J, et al. In vivo fluid dynamics of the Ventura interatrial shunt device in patients with heart failure[J]. ESC Heart Fail, 2024. DOI:10.1002/ehf2.14859. Online ahead of print.
• [23] Stone GW. American College of Cardiology Annual Scientific Session(ACC)2024, Atlanta, GA, April6, 2024. https：//www.acc.org/latest-in-cardiology/clinicaltrials/2024/04/04/04/11/relieve-hf.
• [24] Rodés-Cabau J, Bernier M, Amat-Santos IJ, et al. Interatrial shunting for heart failure:early and late results from the firstin-human experience with the v-wave system[J]. JACC Cardiovasc Interv, 2018, 11(22):2300-2310. DOI:10.1016/j.jcin.2018.07.001.
• [25] Sun W, Zou H, Yong Y, et al. The RAISE trial:a novel device and first-in-man trial[J]. Circ Heart Fail, 2022, 15(4):e008362. DOI:10.1161/CIRCHEARTFAILURE.121.008362.
• [26] S?ndergaard L, Reddy V, Kaye D, et al. Transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel interatrial implant to lower left atrial pressure[J]. Eur J Heart Fail, 2014,16(7):796-801. DOI:10.1002/ejhf.111.
• [27] Baumgartner H, De Backer J, Babu-Narayan SV, et al. 2020ESC Guidelines for the management of adult congenital heart disease[J]. Eur Heart J, 2021, 42(6):563-645. DOI:10.1093/eurheartj/ehaa554.
• [28]中国医师协会心血管内科医师分会结构性心脏病专业委员会，中国医师协会心血管内科医师分会心力衰竭专业委员会，中国医师协会心血管外科医师分会结构性心脏病专业委员会，等.房间隔分流器治疗射血分数保留心力衰竭：中国专家认识和建议[J].中国介入心脏病学杂志，2020,28(12):661-666. DOI:10.3969/j.issn.1004-8812.2020.12.001.
• [29] Litwin SE, Komtebedde J, Hu M, et al. Exercise-induced left atrial hypertension in heart failure with preserved ejection fraction[J]. JACC Heart Fail, 2023, 11(8 Pt 2):1103-1117.DOI:10.1016/j.jchf.2023.01.030.
• [30] Guazzi M, Ghio S, Adir Y. Pulmonary hypertension in HFpEF and HFrEF:JACC review topic of the week[J]. J Am Coll Cardiol, 2020, 76(9):1102-1111. DOI:10.1016/j.jacc.2020.06.069.